Epirubicin Hydrochloride

Adults: Where possible, to lower the risk of cardiotoxicity in patients who start Epirubicin after stopping other cardiotoxic agents, especially those with long half-lives such as Trastuzumab, Epirubicin-based therapy should be delayed until those agents have cleared from the circulation. Epirubicin Injection should be given by intravenous infusion. Epirubicin is given in repeated cycles of 3 to 4 weeks. The total dose of Epirubicin may be given on day 1 of each cycle, or divided equally and given on days 1 and 8 of each cycle. The recommended dose of Epirubicin is 100 to 120 mg/m². The following regimens are recommended. CEF-120: Cyclophosphamide 75 mg/m² orally on days 1 to 14, Epirubicin 60 mg/m² intravenously on days 1 and 8, and 5-Fluorouracil 500 mg/m² intravenously on days 1 and 8, repeated every 28 days for 6 cycles. FEC-100: 5-Fluorouracil 500 mg/m², Epirubicin 100 mg/m² and Cyclophosphamide 500 mg/m², with all drugs given intravenously on day 1 and repeated every 21 days for 6 cycles. Patients receiving the 120 mg/m² regimen of Epirubicin should be given prophylactic antibiotic therapy. Or, as directed by the registered physician.